Flexibility Is Key To Making England’s Innovative Medicines Fund Work
Stakeholders are calling for NHS England and NHS Improvement (NHSE&I) and the health technology assessment body NICE to bring more flexibility into England’s new Innovative Medicines Fund, which is due for launch later in 2021.
You may also be interested in...
Initial optimism about the prospects of speeding up access to rare disease treatments through a new £340m dedicated fund has waned as companies question whether the detailed proposals are workable in practice.
England’s Innovative Medicines Fund is aimed at providing earlier access to promising new treatments, including gene therapies, when further data is needed for routine commissioning.
While they await further details on England’s new Innovative Medicines Fund, industry and other stakeholders are asking questions about how far the fund – due for launch later this year – will be adapted to fit non-cancer therapies.